Dr. Jon Terrett, Ph.D., is vice president of oncology discovery for CytomX. Dr. Terrett brings to CytomX an impressive track record for identifying and progressing genomic and proteomic-derived oncology targets from initial target discovery through validation, pre-clinical efficacy, toxicology and IND filings. Prior to joining CytomX in 2014, he held various scientific roles throughout the biotech and pharmaceutical industries. Most recently, he served as chief scientific officer at Oxford Biotherapeutics, furthering antibody drugs and ADCs for the treatment of cancer.
He also has provided scientific leadership through the director role at companies including Medarax, CellTech and Oxford Glycosciences, and he served as senior investigator at Smithkline Beecham. Dr. Terrett earned a Bachelor of Science in genetics at the University of Sheffield and a doctorate in genetics at University of Nottingham.